Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
José Luis Casado & Sara Bañón. (2015) Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection. Expert Review of Clinical Pharmacology 8:6, pages 709-718.
Read now
Read now
Tae Eun Park, Abdilahi Mohamed, Julie Kalabalik & Roopali Sharma. (2015) Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Review of Anti-infective Therapy 13:10, pages 1195-1212.
Read now
Read now
Giuliano Rizzardini & Patrizia Zucchi. (2011) Abacavir and lamivudine for the treatment of human immunodeficiency virus. Expert Opinion on Pharmacotherapy 12:13, pages 2129-2138.
Read now
Read now
B. young, T. Vanig, E. DeJesus, T. Hawkins, M. St. Clair, B. Stancil & B. Ha. (2011) 96-Week Results of a Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: The SHIELD Trial. HIV Clinical Trials 12:4, pages 228-233.
Read now
Read now
Articles from other publishers (13)
Sebastiano Rizzardo, Massimiliano Lanzafame, Emanuela Lattuada, Damiano Bragantini, Stefano Nicolè, Leonardo Calza & Evelina Tacconelli. (2019) Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study. International Journal of STD & AIDS 30:5, pages 467-471.
Crossref
Crossref
Lisa L. RossDenise ShortinoMark S. Shaefer. (2018) Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States. AIDS Research and Human Retroviruses 34:8, pages 672-679.
Crossref
Crossref
Akihito Suzuki, Yuki Uehara, Mizue Saita, Akihiro Inui, Hiroshi Isonuma & Toshio Naito. (2016) Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naïve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot Analysis. Japanese Journal of Infectious Diseases 69:1, pages 33-38.
Crossref
Crossref
Leonardo CalzaIlaria DaneseVincenzo ColangeliGiacomo VandiRoberto ManfrediNicolò GiromettiMarco BorderiLucia AppolloniCristina PuggioliPierluigi Viale. (2014) Skeletal Muscle Toxicity in HIV-1-Infected Patients Treated with a Raltegravir-Containing Antiretroviral Therapy: A Cohort Study. AIDS Research and Human Retroviruses 30:12, pages 1162-1169.
Crossref
Crossref
Suman Srinivasa & Steven K Grinspoon. (2014) MECHANISMS IN ENDOCRINOLOGY: Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. European Journal of Endocrinology 170:5, pages R185-R202.
Crossref
Crossref
Wan-gang Gu, Denis Tsz-Ming Ip, Si-jie Liu, Joseph H. Chan, Yan Wang, Xuan Zhang, Yong-tang Zheng & David Chi-Cheong Wan. (2014) 1,4-Bis(5-(naphthalen-1-yl)thiophen-2-yl)naphthalene, a small molecule, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular Lens epithelium-derived growth factor. Chemico-Biological Interactions 213, pages 21-27.
Crossref
Crossref
Bruno Hoen, Fabrice Bonnet, Constance Delaugerre, Pierre Delobel, Cécile Goujard, Marianne L’Hénaff, Renaud Persiaux, David Rey, Christine Rouzioux, Anne-Marie Taburet & Philippe Morlat. (2014) French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults. Journal of the International AIDS Society 17:1, pages 19034.
Crossref
Crossref
Linda Battalora, Amy Thomas, Brian Wine, Belinda Ha & Benjamin Young. (2014) Changes in Bone Mineral Density through 96 Weeks in Antiretroviral-Naïve HIV-1 Infected Patients Receiving Abacavir/Lamivudine and Raltegravir in the SHIELD Trial. World Journal of AIDS 04:01, pages 38-44.
Crossref
Crossref
P. Monteiro, I. Perez, J. Pich, J. M. Gatell & E. Martinez. (2012) Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study. Journal of Antimicrobial Chemotherapy 68:2, pages 404-408.
Crossref
Crossref
Esteban MartínezPolyana M. d'AlbuquerqueIgnacio PérezJudit PichJosé M. Gatell. (2013) Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir. AIDS Research and Human Retroviruses 29:2, pages 235-241.
Crossref
Crossref
Frederick J. Lee & Andrew Carr. (2012) Tolerability of HIV integrase inhibitors. Current Opinion in HIV and AIDS 7:5, pages 422-428.
Crossref
Crossref
Amedeo Capetti, Simona Landonio, Paola Meraviglia, Antonio Di Biagio, Sergio Lo Caputo, Gaetana Sterrantino, Adriana Ammassari, Barbara Menzaghi, Marco Franzetti, Giuseppe Vittorio De Socio, Giovanni Pellicanò, Elena Mazzotta, Alessandro Soria, Marianna Meschiari, Michele Trezzi, Lolita Sasset, Benedetto Maurizio Celesia, Patrizia Zucchi, Sara Melzi, Elena Ricci & Giuliano Rizzardini. (2012) 96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience. PLoS ONE 7:7, pages e39222.
Crossref
Crossref
Akil Jackson, Graeme Moyle, Laura Dickinson, David Back, Saye Khoo, Jessica Taylor, Keerti Gedela, George Abongomera, Brian Gazzard & Marta Boffito. (2012) Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects. Antiviral Therapy 17:1, pages 19-24.
Crossref
Crossref